Abstract: The present invention relates to a constructed oligosaccharide cluster, optionally bonded to an immunogenic protein, that can be administered to a subject to induce an immune response for increasing production of 2G12 and/or used in assays as reactive sites for determining compounds that inactivate and/or bind the high-mannose oligosaccharide cluster. Compositions comprising these clusters, methods of using these clusters and compositions are disclosed.
Type:
Grant
Filed:
October 14, 2003
Date of Patent:
July 7, 2009
Assignee:
University of Maryland Biotechnology Institute
Abstract: The present invention relates to isolation of a novel Hepatitis C virus, more particularly, the present invention relates to a viral class Hepatitis C, polypeptides, polynucleotide, vaccine and antibodies derived there from.
Type:
Grant
Filed:
November 2, 2007
Date of Patent:
July 7, 2009
Assignee:
Sudershan Biotech Ltd.
Inventors:
Guntaka Venkata Ramareddy, Chittoor Mohammad Habibullah, Mohammad Nanne Khaja, Chandra Madhavi
Abstract: The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.
Abstract: Peptides which bind to selected receptor molecules are identified by screening libraries which encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, and bacteriophage particles are then screened against the receptors of interest. Peptides having a wide variety of uses, such as therapeutic or diagnostic reagents, may thus be identified without any prior information on the structure of the expected ligand or receptor molecule.
Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
Abstract: The present invention relates to methods of treating or preventing a disease, disorder or condition associated with a viral infection using a dosing and resting regimen for administering a pharmaceutical composition that provides ARP.
Abstract: Means and methods are provided for the production of mammalian viruses comprising: infecting a culture of immortalized human cells with the virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages are that human cells of the present invention can be cultured under defined serum free conditions, and the cells show improved capability for propagating virus. In particular, methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity to use whole chicken embryos for the production of influenza vaccines. The method provides also for the continuous or batchwise removal of culture media. As such, the invention allows the large-scale, continuous production of viruses to a high titer.
Type:
Grant
Filed:
June 8, 2006
Date of Patent:
June 23, 2009
Assignee:
Crucell Holland B.V.
Inventors:
Maria Grazia Pau, Alphonsus G. C. M. UytdeHaag
Abstract: The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.
Type:
Grant
Filed:
November 28, 2005
Date of Patent:
June 23, 2009
Assignee:
Bayer Schering Pharma AG
Inventors:
Terry Hermiston, Fang Jin, Peter Kretschmer
Abstract: The invention relates to a novel bacteriophage which is lytic for species of the genus Methylobacterium, Human Blood Bacterium (HBB) or both, and derivatives, progeny and recombinant and mutated forms thereof. The invention further relates to compositions, methods and kits for using the bacteriophage of the invention in agricultural and therapeutic settings.
Abstract: The invention relates to the process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from said process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows the introduction of mutations, deletions and/or insertions. The process can be used to modify the virulence of NDV, thereby generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, thus allowing the generation of live NDV marker vaccines which can be serologically distinguished from NDV field strains.
Type:
Grant
Filed:
April 15, 2004
Date of Patent:
June 16, 2009
Assignee:
ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.
Inventors:
Bernardus Petrus Hubertus Peeters, Olav Sven de Leeuw, Guus Koch, Arnoud Leonard Josef Gielkens
Abstract: The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.
Type:
Grant
Filed:
January 3, 2008
Date of Patent:
June 16, 2009
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Barbara Upmeier, Dittmar Schlieper, Frederic Donie
Abstract: The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof, and methods of preparing such conjugates. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.
Type:
Grant
Filed:
August 2, 2007
Date of Patent:
June 16, 2009
Assignees:
Nektar Therapeutics AL, Corporation, National Institute of Heatlh
Inventors:
M. Elizabeth Snell, Michael J. Roberts, Toshiyuki Mori, Barry R. O'Keefe, Michael R. Boyd
Abstract: Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.
Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.
Type:
Grant
Filed:
May 24, 2004
Date of Patent:
May 26, 2009
Assignees:
Panacos Pharmaceuticals, Inc., The United States of America as represented by the Department of Health and Human Services
Inventors:
Karl Salzwedel, Feng Li, Carl T. Wild, Graham P. Allaway, Eric O. Freed
Abstract: A recombinant herpesvirus (excluding infectious laryngotracheitis virus) having a DNA that encodes a polypeptide comprising 429 amino acids at the amino terminal end of a protein encoded by the gB gene of infectious laryngotracheitis virus or a polypeptide in which one or a plurality of amino acids have been deleted, added, or substituted in said polypeptide.
Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBE30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.
Type:
Grant
Filed:
September 15, 2005
Date of Patent:
May 19, 2009
Assignees:
Institute National de la Sante et de la Recherche Medicale-Inserm, Assitance Publique-Hopitaux de Paris, Institut Pasteur
Abstract: The present invention is related to an in vitro diagnostic assay of enteroviruses, based on the revealing of an immunologic reaction of antigen-antibody recognition type, using antigens or epitopes thereof that do not induce antiviral neutralising antibodies but induce “facilitating” antibodies which increase the viral infection.
Type:
Grant
Filed:
February 9, 2004
Date of Patent:
May 19, 2009
Assignees:
Universite de Lille 2 Droit Et Sante, Centre Hospitalier Regional Universitaire de Lille (Chru de Lille)
Inventors:
Wassim Chehadeh, Didier Hober, Ahmed Bouzidi
Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae , of the family Paramyxoviridae . The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.
Type:
Grant
Filed:
February 21, 2003
Date of Patent:
May 12, 2009
Assignees:
MedImmune, LLC, ViroNovative BV
Inventors:
Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
Abstract: The present invention provides multi-antigenic constructs comprising one or more carbohydrate antigens having the formula: wherein R1, R2A, R2B, R3, R4, W1, W2 and W3 are as defined herein; and additionally provides compositions thereof, and methods for their use in the treatment and/or prevention of HIV infection, and methods for inducing HIV-specific antibodies in a subject, comprising administering to a subject in need thereof, an effective amount of any of the inventive compounds as disclosed herein, either in conjugated form or unconjugated and in combination with a suitable immunogenic carrier. In another aspect, the invention provides an antibody or antibody fragment which binds specifically to a gp120 glycan or glycopeptide of the invention.
Type:
Grant
Filed:
June 3, 2005
Date of Patent:
May 12, 2009
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Samuel J. Danishefsky, Vadim Dudkin, Xudong Geng, Mihirbaran Mandal, Isaac Kraus